GPT and metabolic dysfunction-associated steatotic liver disease: In a randomized control trial on 64 patients with T2DM and NAFLD that received dulaglutide or the standard treatment, Kuchay et al. [50] demonstrated that dulaglutide reduced GGT levels (−13.1 U/L, p = 0.025), with no significant differences on ALT (−13.1 U/L, p = 0.10), AST (−9.3 U/L, p = 0.075) or liver stiffness measurements.